Pancreatic Cancer Research

ResearcherUniversity of LondonActive in the last 2 years

Marco Falasca

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9801-7235; OpenAlex author ID A5089714768. Sources: OpenAlex.

Their work

Papers
35 (first author 8, last author 20)
Trials
0
Grants
0
Labs led
2
Collaborators
42
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 5 papers · 2019: 5 papers · 2020: 3 papers · 2021: 3 papers · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers

Papers 35

  1. Oncogenic small extracellular vesicles enriched in sphingosine-1-phosphate play a crucial role in pancreatic cancer progression. Last author DOI 10.1016/j.cellsig.2025.111775↗
  2. Oncogenic proteome of pancreatic cancer extracellular vesicles: sodium/myo-inositol cotransporter as a potential marker. Last author DOI 10.1038/s41392-025-02232-9↗
  3. Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota. Last author DOI 10.3390/ijms26167733↗
  4. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Co-author DOI 10.1002/pmic.202300067↗
  5. Extracellular vesicles in pancreatic cancer: a new era in precision medicine. First author DOI 10.21037/tgh-23-53↗
  6. Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models. Last author DOI 10.3390/ijms25042340↗
  7. Can the molecules carried by extracellular vesicles help to diagnose pancreatic cancer early? Last author DOI 10.1016/j.bbagen.2023.130387↗
  8. Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity. Last author DOI 10.1016/j.semcancer.2023.09.004↗
  9. Bile Acids and Microbiota Interplay in Pancreatic Cancer. Last author DOI 10.3390/cancers15143573↗
  10. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle. Last author DOI 10.1016/j.hbpd.2021.09.004↗
  11. Extracellular vesicles derived from pancreatic cancer cells are enriched in the growth factor Midkine. Last author DOI 10.1016/j.jbior.2021.100857↗
  12. Targeting the Endocannabinoidome in Pancreatic Cancer. First author DOI 10.3390/biom12020320↗
  13. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance. Last author DOI 10.3390/cancers14235793↗
  14. Exosomal long non-coding RNAs in the diagnosis and oncogenesis of pancreatic cancer. Last author DOI 10.1016/j.canlet.2020.12.005↗
  15. Exosomal integrins and their influence on pancreatic cancer progression and metastasis. Last author DOI 10.1016/j.canlet.2021.03.010↗
  16. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. First author DOI 10.3390/cancers13205224↗
  17. The intricate relationship between diabetes, obesity and pancreatic cancer. First author DOI 10.1016/j.bbcan.2019.188326↗
  18. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic c… Co-author DOI 10.1016/j.jbior.2019.100672↗
  19. Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers12010250↗
  20. Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. Last author DOI 10.1016/j.jbior.2019.02.001↗
  21. ABCC3 is a novel target for the treatment of pancreatic cancer. Last author DOI 10.1016/j.jbior.2019.04.004↗
  22. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. Last author DOI 10.1186/s13046-019-1191-2↗
  23. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. Last author DOI 10.1186/s13046-019-1308-7↗
  24. Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation. Last author DOI 10.3390/cancers11111695↗
  25. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Last author DOI 10.1016/j.jbior.2017.11.007↗
  26. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Co-author DOI 10.1016/j.jbior.2018.06.002↗
  27. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Last author DOI 10.1038/s41388-018-0390-1↗
  28. Epithelial plasticity is crucial for pancreatic cancer metastatic organotropism. First author DOI 10.21037/atm.2018.10.16↗
  29. ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward? First author DOI 10.3748/wjg.v24.i29.3222↗
  30. The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance. First author DOI 10.3390/cancers9100142↗
  31. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Last author DOI 10.3390/ijms18071338↗
  32. Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer. Co-author DOI 10.4251/wjgo.v9.i1.37↗
  33. Pancreatic cancer: Current research and future directions. Co-author DOI 10.1016/j.bbcan.2016.01.001↗
  34. Diet and Pancreatic Cancer Prevention. First author DOI 10.3390/cancers7040892↗
  35. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials. Co-author DOI 10.2174/187152011795677382↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ilaria Casari · 11 shared papers, 2015–2025 · strength 2.15
  2. Pratibha Malhotra · 5 shared papers, 2022–2025 · strength 1.32
  3. Ranjith Palanisamy · 4 shared papers, 2022–2025 · strength 1.05
  4. Arunima Panda · 3 shared papers, 2024–2025 · strength 0.94
  5. Krish Ragunath · 3 shared papers, 2024–2025 · strength 0.94
  6. Aleksandra Adamska · 8 shared papers, 2017–2019 · strength 0.90
  7. Alice Domenichini · 7 shared papers, 2017–2022 · strength 0.86
  8. Pat Metharom · 5 shared papers, 2017–2023 · strength 0.65
  9. Aikaterini Emmanouilidi · 4 shared papers, 2018–2025 · strength 0.65
  10. Marina Pajic · 2 shared papers, 2025 · strength 0.57
  11. Norbaini Binti Abdol Razak · 4 shared papers, 2017–2023 · strength 0.56
  12. Jordan Fyfe · 2 shared papers, 2023–2025 · strength 0.48
  13. Omar Elaskalani · 4 shared papers, 2017–2020 · strength 0.41
  14. Eunice Eugenia Robless · 2 shared papers, 2021 · strength 0.38
  15. Silvano Paternoster · 2 shared papers, 2019–2020 · strength 0.35
  16. Zhihong Xu · 2 shared papers, 2021–2024 · strength 0.34
  17. Minoti Vivek Apte · 2 shared papers, 2021–2024 · strength 0.34
  18. Jeremy S. Wilson · 2 shared papers, 2021–2024 · strength 0.34
  19. Chamini Jayamali Perera · 2 shared papers, 2021–2024 · strength 0.34
  20. Suresh T. Chari · 2 shared papers, 2021–2024 · strength 0.34
  21. Valerio Falasca · 1 shared paper, 2022 · strength 0.33
  22. Riccardo Ferro · 3 shared papers, 2018–2019 · strength 0.24
  23. Vincenzo De Laurenzi · 3 shared papers, 2018–2019 · strength 0.23
  24. S. M. Zahid Hosen · 1 shared paper, 2024 · strength 0.20
  25. Federico Selvaggi · 2 shared papers, 2011–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.